Introduction {#tca12369-sec-0005}
============

Our prospective phase II study of chemoradiation therapy (CRT) for esophageal cancer (EC) using involved‐field radiation therapy (IFRT), based on 18‐fluorodeoxyglucose (^18^FDG) positron‐emission tomography (PET), indicated the efficacy of IFRT in the treatment of inoperable EC, primarily squamous cell carcinoma.[1](#tca12369-bib-0001){ref-type="ref"} The primary end point was to determine that isolated out‐of‐field loco‐regional nodal recurrence did not occur in more than six cases. Recent studies have examined prognostic factors in EC. According to Yutong *et al.,* multivariate analysis indicated that age, pathological type, tumor node metastasis (TNM) stage, surgery and neutrophil‐lymphocyte ratio were independent risk factors for 820 pathologically confirmed cases of EC (odds ratio ≥ 3.5/\< 3.5 = 1.29).[2](#tca12369-bib-0002){ref-type="ref"} According to Boggs, in 67 patients treated for EC with CRT followed by esophagectomy, gross tumor volume (GTV)‐primary was the only multivariate predictor of progression‐free survival (PFS; *P* = 0.030) and overall survival (OS; *P* = 0.0012) at five years, rather than traditional TNM staging.[3](#tca12369-bib-0003){ref-type="ref"} In this study, the prognostic factors affecting survival after this treatment method are reported as a secondary endpoint. We sought to determine prognostic factors in patients that received homogenous treatment for EC, such as IFRT and concurrent chemotherapy, to ascertain the treatment method with the worst prognosis in order to improve the survival in these patients. At present, three‐year OS is only around 50%.

Methods {#tca12369-sec-0006}
=======

Eligible patients included adults with newly diagnosed, untreated, inoperable stage I--IV EC. Stage IV cases included had supraclavicular and/or para‐aortic lymph nodes (LNs) only, without distant organ metastasis. Patients received 80 mg/m^2^ nedaplatin per day on day 1, 800 mg/m^2^ 5‐fluorouracil on days 1--4 intravenously repeated every 28 days for two to four cycles, and combined IFRT. Elective nodal irradiation was not performed. Irradiation was applied only to the primary tumor and positive lymph nodes. Age criteria were 20--85 years old.

Radiotherapy planning and target volume definition {#tca12369-sec-0007}
--------------------------------------------------

Enhanced computed tomography (CT) and/or PET and endoscopic extension were used to define GTV for each patient. All LNs with a diameter at least 1 cm in the short axis in CT or positive by ^18^FDG‐PET (excluding physiological accumulation) were included in the GTV. The positive was defined as more than 2.5 of maximum standardized uptake value (SUVmax). The GTV was contoured on the planning CT by referring to the PET/CT images on the monitor adjacent to the Pinnacle[3](#tca12369-bib-0003){ref-type="ref"} planning machine. We did not co‐register the PET/CT images with the planning‐CT in Pinnacle. All patients had available PET/CT information. The clinical target volume (CTV)‐GTV margin was 2 cm in the craniocaudal direction and 0 cm in the other four directions for the primary tumor. CTV was equal to GTV for metastatic LNs. The planning target volume (PTV)‐CTV margin was 1 cm in the craniocaudal direction and 0.5 cm in the other four directions. The heterogeneity corrections of collapsed cones convolution superposition were used. Volumetric modulated arc therapy was also used when necessary in terms of dose constraints for both target volume and organ at risk. All patients received selective LN irradiation and were treated with 50.4 Gy delivered over 5.6 weeks at 1.8 Gy per fraction or 50 Gy in 25 fractions over five weeks.

Patients {#tca12369-sec-0008}
--------

Serum tumor markers, carcinoembryonic antigen (CEA), squamous cell carcinoma‐related antigen (SCC), cytokeratin 19 fragment (CYFRA), and p53 antibody, were obtained before CRT.

The chemotherapy relative dose intensity (RDI) was calculated as follows:[4](#tca12369-bib-0004){ref-type="ref"}

RDI = (total chemotherapy cycle number administered/4 cycles) × (chemotherapy dose administered per cycle/100% dose) × (28 days/interval between chemotherapy cycles) × 100 (%).

Karnofsky performance status (KPS) before treatment was 70--80% in 19 cases. The subsites of the primary tumors included cervical (Ce), upper (Ut), middle (Mt), and lower thoracic (Lt) portions, with distributions at 5%, 19%, 49%, and 27%, respectively (Table [1](#tca12369-tbl-0001){ref-type="table-wrap"}). Tumor length in the craniocaudal direction before CRT was over 5.0 cm in 33 cases. The positive rates of SCC, CYFRA, CEA, and p53 tumor markers were 48.4% (32/62 cases), 16.7% (10/60), 27.9% (17/61), and 17.7% (11/62), respectively (Table [1](#tca12369-tbl-0001){ref-type="table-wrap"}).

###### 

Clinicopathological characteristics of patients with esophageal cancer

  Factors              N    1‐year OS (%)   2‐year OS (%)   3‐year OS (%)   MST (month)   *P* (log‐rank)                
  ------------------- ---- --------------- --------------- --------------- ------------- ---------------- ------ ------ ----------
  Total                63       68.3             5.9            57.1            6.2            47.5        6.3    31.5  
  Age                                                                                                                   
  \<68 years           32       65.6             8.4            56.2            8.8            50.0        8.8    41.8     0.20
  ≥68 years            31       71.0             8.2            58.1            8.9            45.2        8.9    31.5  
  KPS                                                                                                                   
  ≥90%                 44       79.5             6.1            65.9            7.2            54.4        7.5    39.2    0.027
  \<90%                19       42.1            11.3            36.8           11.1            31.6        10.7   7.6   
  Stage                                                                                                                 
  I                    9        88.9            10.5            88.9           10.5            88.9        10.5    NE     0.0087
  II                   10        100                             100                           70.0        14.5   53.5  
  III                  27       59.3             9.5            48.1            9.6            44.1        9.6    22.0  
  IV                   17       52.9            12.1            29.4           11.1            17.6        9.3    13.0  
  T stage                                                                                                               
  T1                   10       90.0             9.5            90.0            9.5            80.0        12.7    NE     0.066
  T2                   7         100                             100                           85.7        13.2   51.1  
  T3                   22       68.2             9.9            54.5           10.6            40.0        10.6   28.6  
  T4                   24       50.0            10.2            33.3            9.6            29.2        9.3    11.8  
  N stage                                                                                                               
  N0                   17       94.1             5.7            94.1            5.7            88.2        7.8     NE    0.000086
  N1                   15       80.0            10.3            66.7           12.2            53.3        12.9   53.5  
  N2                   18       50.0            11.8            38.9           11.5            26.7        10.7   14.8  
  N3                   13       46.2            13.8            23.1           11.7            15.4        10.0   9.2   
  M stage                                                                                                               
  M0                   46       73.9             6.5            67.4            6.9            58.5        7.3    51.1    0.0042
  M1                   17       52.9            12.1            29.4           11.1            17.6        9.3    13.0  
  Tumor location                                                                                                        
  Ce                   3        66.7            27.2            66.7           27.2            66.7        27.2    NE      0.29
  Ut                   12       58.3            14.2            41.7           14.2            25.0        12.5   51.1  
  Mt                   31       74.2             7.9            58.1            8.9            51.6        9.0    39.4  
  Lt                   17       64.7            11.6            64.7           11.6            52.9        12.1   15.7  
  Pathological type                                                                                                     
  SqCC                 59       67.8             6.1            55.9            6.5            45.6        6.5    29.8     0.37
  AC                   4        75.0            21.7            75.0           21.7            75.0        21.7   53.8  
  Dysphagia score                                                                                                       
  1                    9        66.7            15.7            66.7           15.7            55.6        16.6    NE    0.00017
  2                    17       41.2            11.9            17.6            9.3            17.6        9.3    10.6  
  3                    9        66.7            15.7            44.4           16.6            11.1        10.5   13.9  
  4(normal)            28       85.7             6.6            82.1            7.2            75.0        8.2     NA   
  Tumor length                                                                                                          
  ≤ 5.0 cm             37       67.6             7.7            56.8            8.1            45.9        8.2    31.5     0.91
  \> 5.0 cm            26       69.2             9.1            57.7            9.7            50.0        9.8    33.0  
  SCC                                                                                                                   
  Low                  30       73.3             8.1            73.3            8.1            66.7        8.6     NE     0.0054
  High                 32       62.5             8.6            43.8            8.8            30.7        8.3    17.6  
  NE                   1                                                                                                
  CYFRA                                                                                                                 
  Low                  50       72.0             6.4            64.0            6.8            53.9        7.1    39.2     0.13
  High                 11       54.5            15.0            36.4           14.5            27.3        13.4   12.3  
  NE                   2                                                                                                
  CEA                                                                                                                   
  Low                  44       68.2             7.0            56.8            7.5            45.2        7.5    30.7     0.77
  High                 17       70.6            11.1            64.7           11.6            58.8        11.9   42.7  
  NE                   2                                                                                                
  p53                                                                                                                   
  Low                  51       68.6             6.5            58.8            6.9            48.9        7.0    35.6     0.43
  High                 11       63.6            14.5            54.5           15.0            45.5        15.0   29.8  
  NE                   1                                                                                                
  GTV‐60 cc                                                                                                             
  ≤ 60 cc              29       86.2             6.4            82.8            7.0            75.9        8.0     NE    0.00011
  \> 60 cc             34       52.9             8.6            35.3            8.2            22.9        7.3    13.4  
  RDI‐50%                                                                                                               
  ≤ 50%                28       57.1             9.4            42.9            9.4            35.7        9.1    15.4    0.063
  \> 50%               35       77.1             7.1            68.6            7.9            56.9        8.4    51.1  
  RDI‐60%                                                                                                               
  ≤ 60%                29       58.6             9.2            44.8            9.2            34.5        8.8    17.8    0.052
  \> 60%               34       76.5             7.3            67.6            8.0            58.7        8.5    53.5  
  RDI‐70%                                                                                                               
  ≤ 70%                32       59.4             8.7            46.9            8.8            37.5        8.6    18.1    0.064
  \> 70%               31       77.4             7.5            67.7            8.4            57.9        8.9    51.1  

AC, adenocaricinoma; Ce, cervix; CEA, carcino‐embryonic antigen; CYFRA, cytokeratin 19 fragment; GTV, gross tumor volume; KPS, Karnofsky Performance Status; Lt, lower thoracic; MST ,median survival time; Mt, middle thoracic; NE, not evaluated; OS, overall survival; RDI, relative dose intensity; SCC, squamous cell carcinoma‐related antigen; SE, standard error; SqCC, squamous cell carcinoma; SE, standard error; Ut, upper thoracic.

Statistical analysis {#tca12369-sec-0009}
--------------------

Kaplan--Meier method was used for OS estimation and log‐rank for *P* value in comparisons with each group. Survival durations were calculated from the start of CRT. The proportional hazard model was used for multivariate analyses of OS. Multivariate analysis was performed by stepwise variable selection using Bayesian information criterion. The explanatory variables included age (\<68 vs. ≥68 years), tumor length (≥5 cm vs. \<5 cm), cT stage, cN stage, cM stage, GTV (≥ 60cc vs. \< 60cc), KPS (\<90% vs. ≥90%), histopathological type (SCC vs. other), and RDI (≥50% vs. \<50%). *P* \< 0.05 was considered statistically significant. The final follow‐up date was 25 April 2016.

Results {#tca12369-sec-0010}
=======

From September 2009 to July 2012, 63 patients were enrolled. The primary end point of isolated out‐of‐field loco‐regional nodal recurrence was seen in only three patients.

The mean ± standard error (SE) for PTV was 293.0 ± 25.1 cc. The average ± SE for GTV, CTV, and irradiated volume was 82.4 ± 9.6 cc, 116.3 ± 13.1 cc, and 421.9 ± 30.2 cc, respectively. Chemotherapy RDI was 0--24% in four cases, 25--49% in 24, 50--74% in nine, and 75--100% in 26 cases. Salvage surgery was performed in 11 patients (17.5%) as a result of residual (3 cases) or recurrent (8) disease. Two of these cases received exploratory laparotomy as salvage surgery.

The median follow‐up duration in the 23 (37%) living patients was 56.7 months (range 30.7--76.2). Estimated two, three, and four‐year OS for all 63 cases by Kaplan--Meier method were 57.1% (95% confidence interval \[CI\]) 44--68.3%), 47.5% (95% CI 34.8--59.2%), and 44.2% (95% CI 31.8--56%), respectively. Median OS duration was 31.5 months (95% CI 17.5--53.8). PFS rates at two, three, and four‐years were 50.7%, 44.9%, and 43%, respectively, and the median PFS was 27.3 months (95% CI 12‐NA).

Univariate analyses for OS by log‐rank test were performed according to age, KPS, initial stage (including T, N, and M stage), tumor location, pathological type, dysphagia score, tumor length, initial tumor markers, GTV (= primary tumor plus positive LNs), and RDI (Table [1](#tca12369-tbl-0001){ref-type="table-wrap"}). Among these factors, KPS \< 90% (3‐year OS 54.4% vs. 31.6%; *P* = 0.027), initial stage (*P* = 0.0087), T stage (*P* = 0.066), N stage (*P* = 0.000086), M stage of M1 (58.5% vs. 17.6%; *P* = 0.0042), dysphagia score (*P* = 0.00017), SCC \> 1.5 ng/mL (66.7% vs. 30.7%; *P* = 0.0054), GTV \> 60cc (75.9% vs. 22.9%; *P* = 0.00011; Fig [1](#tca12369-fig-0001){ref-type="fig"}), and RDI ≤ 50% (56.9% vs. 35.7%; *P* = 0.063; Fig [2](#tca12369-fig-0002){ref-type="fig"}) were found to be associated with significantly or marginally poor prognosis. There was no significant correlation between OS and age (*P* = 0.20), tumor location (*P* = 0.29), pathological type (*P* = 0.37), tumor length (*P* = 0.91), CYFRA (*P* = 0.13), CEA (*P* = 0.77), or p53 (*P* = 0.43).

![Kaplan--Meier survival curves in 63 patients with esophageal carcinoma, comparing gross tumor volume ≤60 cc and \>60 cc (*P* = 0.00011). OS, overall survival.](TCA-7-564-g001){#tca12369-fig-0001}

![Kaplan--Meier survival curves in 63 patients with esophageal carcinoma, comparing relative dose intensity of ≤50% and \>50% (*P* = 0.063). OS, overall survival.](TCA-7-564-g002){#tca12369-fig-0002}

Multivariate analyses for OS by proportional hazard model were performed (Table [2](#tca12369-tbl-0002){ref-type="table-wrap"}). GTV ≥ 60cc (hazard ratio \[HR\] 4.35; *P* = 0.00040), RDI ≤ 50% (HR 3.52; *P* = 0.00034), and cN‐stage (HR 3.40; *P* = 0.0020) remained associated with significantly poor prognosis. However, the significant differences disappeared in KPS, and cT and cM stages.

###### 

Multivariate analyses for overall survival

  Factors      Hazard ratio   Lower 95% CI   Upper 95% CI   *P*
  ------------ -------------- -------------- -------------- ---------
  cN2‐3        3.40           1.57           7.37           0.0020
  GTV ≥ 60cc   0.23           0.10           0.52           0.00040
  RDI ≤ 50%    3.52           1.77           7.00           0.00034

CI, confidence interval; GTV, gross tumor volume; RDI, relative dose intensity.

Discussion {#tca12369-sec-0011}
==========

We present a secondary analysis of a data set from a prospective, single institution phase II trial evaluating a large number of potential prognostic features for EC treated with IFRT and concurrent chemotherapy. This study found prognostic factors that predicted OS in the 63 patients enrolled. Elective nodal irradiation is unnecessary and, thus, is omitted in the radiation field when using concurrent CRT combined with nedaplatin plus 5‐fluorouracil. The finding that GTV60cc is a prognostic factor was limited to this particular CRT method in our study; however, we believe our results apply to all CRT for EC. Our primary end point of isolated out‐of‐field loco‐regional nodal recurrence after CRT for EC using IFRT based on ^18^FDG‐PET was seen in only three patients; the expected rate was less than 5%, based on our previous research.[1](#tca12369-bib-0001){ref-type="ref"} In this study, RDI ≤ 50% (28 cases) and GTV in addition to clinical T and cN stages were associated with a significantly poor OS prognosis after definitive CRT using IFRT for EC. The overall impact of such findings is small given the size of the patient sample size. As expected, TNM staging and KPS were prognostic factors.

Tumor length was determined as a prognostic factor of EC.[5](#tca12369-bib-0005){ref-type="ref"}, [6](#tca12369-bib-0006){ref-type="ref"}, [7](#tca12369-bib-0007){ref-type="ref"}, [8](#tca12369-bib-0008){ref-type="ref"}, [9](#tca12369-bib-0009){ref-type="ref"}, [10](#tca12369-bib-0010){ref-type="ref"}, [11](#tca12369-bib-0011){ref-type="ref"}, [12](#tca12369-bib-0012){ref-type="ref"} Data from the Japanese esophageal carcinoma registration database between 1969 and 1980 demonstrated that the depth of tumor invasion correlated with the 10‐year survival of EC patients more than the superficial extent of the tumor.[6](#tca12369-bib-0006){ref-type="ref"}, [13](#tca12369-bib-0013){ref-type="ref"} Recent publications have suggested that pathologic esophageal tumor length is directly correlated with long‐term survival; however, most of these data originated in western countries, and the cancer type was predominantly adenocarcinoma.[8](#tca12369-bib-0008){ref-type="ref"}, [11](#tca12369-bib-0011){ref-type="ref"}, [12](#tca12369-bib-0012){ref-type="ref"}, [14](#tca12369-bib-0014){ref-type="ref"}, [15](#tca12369-bib-0015){ref-type="ref"}, [16](#tca12369-bib-0016){ref-type="ref"} The finding that GTV \> 60 cc was associated with a significantly poor OS prognosis may be related to the fact that tumor length is a prognostic factor for survival. However, tumor length \>5 cm was not a prognostic factor for OS in the present study.

Recently, Boggs *et al.* reported that GTV‐primary was a significant multivariate predictor for improved local control (*P* = 0.034), PFS (*P* = 0.030), and OS (*P* = 0.0012) in locally advanced EC patients treated with tri‐modality therapy of CRT followed by esophagectomy.[3](#tca12369-bib-0003){ref-type="ref"} Additionally, they reported that GTV‐primary \>85 cc was the best predictor for local failure (33% vs. 9% if ≤85 cc). They concluded that GTV‐primary was a more powerful predictor of patient outcome than traditional TNM staging. Our results are consistent with their conclusion; however Boggs *et al*. contoured primary and nodal GTV as separate regions of interest rather than together and they adopted preoperative CRT, not definitive CRT.

Bollschweiler *et al*. demonstrated a strong correlation between tumor length and T stage, with tumors measuring less than 3 cm associated with improved survival rates.[17](#tca12369-bib-0017){ref-type="ref"} Although univariate analysis revealed T, N, and M grading and tumor length were of significant prognostic relevance, multivariate analysis concluded that only T, N, and M grading were independent prognostic factors. This remains a controversial area and further research is required to clarify the relevance of tumor length in EC prognosis. In the present study, T and N grading were determined as prognostic factors.

Many previous studies did not distinguish between EC stages II and III. Our stage II clinical results were very good, with a three‐year OS rate of 100%; however, only 10 patients were included.

In the present study, RDI ≤ 50% was a prognostic factor for OS. Therefore, it may be important to administer at least to two cycles of chemotherapy as a standard schedule. However, our results are limited in that it prior to the study we decided that elderly patients would only be treated with two cycles and 80% of the dose administered to younger patients. It has been reported that a higher chemotherapy RDI improves survival in colon cancer, metastatic solid tumors, early stage breast cancer, epithelial ovarian cancer, and renal cell carcinoma.[18](#tca12369-bib-0018){ref-type="ref"}, [19](#tca12369-bib-0019){ref-type="ref"}, [20](#tca12369-bib-0020){ref-type="ref"}, [21](#tca12369-bib-0021){ref-type="ref"}, [22](#tca12369-bib-0022){ref-type="ref"}

This study had a number of limitations. GTV is a somewhat subjective measure because it relies on the physician\'s judgment. Inter‐observer variability in the GTV definition is well known, which could limit the generalizability of the results.[23](#tca12369-bib-0023){ref-type="ref"} Other authors have used only the volume of the primary tumor to predict survival.[24](#tca12369-bib-0024){ref-type="ref"} However, in the present study, the PTV and involved nodes were added to calculate GTV. Because this was a prospective study, cases with poor performance status or with serious complications were excluded.

The results of this study indicated that GTV (\>60 cc), RDI (≤50%), T, and N grading were unfavorable prognostic factors for OS after definitive CRT using IFRT for EC.
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